Vaccine venture
GlaxoSmithKline has formed a joint venture with Shenzhen Neptunus Interlong Bio-Technique that will develop and manufacture influenza vaccines for the Chinese market.

GlaxoSmithKline (
) has formed a joint venture with
that will develop and manufacture influenza vaccines for the Chinese market, including Hong Kong and Macau.
The joint venture, with access to specific local influenza antigens, aims to create vaccines for seasonal, pre-pandemic and pandemic influenza. It is expected that these vaccines will become available over the next few years.
GSK will provide access to its proprietary adjuvant system, which the company says helps to improve efficiency and optimise production by increasing the number of vaccine doses that can be produced using a smaller amount of antigen.
Shenzhen Neptunus will provide additional local manufacturing capacity and R&D expertise. Both companies will provide further investment in manufacturing.
GSK will take a 40 per cent stake in the joint venture for a contribution of cash and assets equivalent to £21m. Shenzhen Neptunus will take a 60 per cent stake for a contribution of cash and assets equivalent to £31m.
Register now to continue reading
Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.
Benefits of registering
-
In-depth insights and coverage of key emerging trends
-
Unrestricted access to special reports throughout the year
-
Daily technology news delivered straight to your inbox
Experts speculate over cause of Iberian power outages
I´m sure politicians will be thumping tables and demanding answers - while Professor Bell, as reported above, says ´wait for detailed professional...